^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
FR Alpha Peptide Vaccine
i
Other names: FR Alpha Peptide Vaccine
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
National Cancer Institute
Drug class:
Immunostimulant
Related drugs:
2years
Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer (clinicaltrials.gov)
P2, N=280, Active, not recruiting, Academic and Community Cancer Research United | Trial primary completion date: Jul 2023 --> Aug 2022
Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 expression
|
cyclophosphamide • FR Alpha Peptide Vaccine • Leukine (sargramostim)
2years
Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer (clinicaltrials.gov)
P2, N=280, Active, not recruiting, Academic and Community Cancer Research United | Recruiting --> Active, not recruiting
Enrollment closed
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 expression
|
cyclophosphamide • FR Alpha Peptide Vaccine • Leukine (sargramostim)
Share via
